Comparative Evaluation of Safety and Efficacy of Dapoxetine, Silodosin, and Citalopram in the Management of Premature Ejaculation

PHASE4CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

January 1, 2025

Study Completion Date

March 1, 2025

Conditions
Premature (Early) Ejaculation
Interventions
DRUG

Oral intake of medication

● Group A: Received Citalopram hydrobromide, starting with 10 mg once daily for 1 week, followed by 20 mg once daily for 10 weeks, and 10 mg daily during the final week (tapered).

DRUG

Oral intake of medication

● Group B: Received Silodosin 4mg, administered orally once daily.

DRUG

Oral intake of medication

● Group C: Received Dapoxetine hydrochloride 30 mg, taken 2 hours before intercourse, on-demand, minimum of 8 times/month for 3 months.

DRUG

Oral intake of medication

● Group D: Received Dapoxetine hydrochloride 30 mg, administered daily.

Trial Locations (1)

Unknown

Beni-Suef university, Banī Suwayf

All Listed Sponsors
lead

Beni-Suef University

OTHER

NCT07113145 - Comparative Evaluation of Safety and Efficacy of Dapoxetine, Silodosin, and Citalopram in the Management of Premature Ejaculation | Biotech Hunter | Biotech Hunter